SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026. The appointment adds public-company financial and capital markets experience as the company continues its global expansion and advances regulatory initiatives.
Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career. She joins SS Innovations after serving as CFO at Vicarious Surgical, another developer of robotic surgical technologies, where she oversaw financial and operational initiatives designed to reduce cash burn and strengthen the company’s balance sheet.
The appointment comes at a pivotal time for SS Innovations, which is pursuing broader commercialization of its SSi Mantra surgical robotic platform while continuing preparations for U.S. Food and Drug Administration review (https://nnw.fm/yY4UM). The company is also expanding internationally, having recently graduated the inaugural class of its SS International Centre for Robotics Surgery (SSICRS) cardiac robotic surgery training program. SSICRS welcomed 33 healthcare professionals from seven countries, underscoring the company’s emphasis on surgeon education alongside technology deployment.
The addition of Romano strengthens SS Innovations' leadership as it navigates the complex regulatory pathway for the SSi Mantra system. The company’s focus on training surgeons globally highlights its strategy to build a skilled user base that can drive adoption of its technology. With Romano’s experience in raising capital and managing finances at a public medtech firm, SS Innovations is better positioned to fund its FDA submission and international expansion efforts.
For the healthcare industry, the progress of SS Innovations signals increasing competition in the surgical robotics market, which has long been dominated by Intuitive Surgical’s da Vinci system. The SSi Mantra, if approved, could offer a more affordable and accessible option for hospitals and surgical centers, potentially expanding the use of robotic surgery in cardiac and other procedures. The training of international surgeons also suggests that the company is building a global ecosystem to support its technology, which could accelerate adoption in regions with growing demand for minimally invasive surgery.
Investors and industry observers will be watching closely as SS Innovations moves toward its FDA submission. The company’s ability to secure regulatory clearance and successfully commercialize the SSi Mantra could reshape the competitive landscape of robotic surgery. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
